Cost-effectiveness of latent tuberculosis infection screening using interferon-gamma release assays among migrants to Japan: a Markov modelling study incorporating social vulnerability and access barriers Authors: Akiko Kowada Published: 2026 ABSTRACT AbstractObjectiveThis study aims to evaluate the cost-effectiveness of latent tuberculosis infection (LTBI) screening strategies using interferon-gamma release assays (IGRAs) among migrants, integrating social vulnerability and access barriers into the modelling framework to support more inclusive public health policy.DesignA Markov state-transition model was constructed from a public healthcare payer perspective over a lifetime horizon.SettingJapan.PopulationA hypothetical cohort of asymptomatic 30-year-old immigrants originating from six high-incidence countries.InterventionsScreening strategies included IGRA-based LTBI testing paired with various preventive treatment regimens: 3-month once-weekly isoniazid plus rifapentine (3HP) under directly observed therapy (DOT), 3HP under self-administered therapy, 1-month daily isoniazid plus rifapentine (1HP) under DOT, 4-month daily self-administered rifampin (4R), 3-month daily self-administered isoniazid plus rifampin, 6-month daily self-administered isoniazid, 9-month daily self-administered isoniazid, pre-entry chest X-ray, postentry chest X-ray, postentry artificial intelligence (AI)-assisted chest X-ray and no screening.Main outcome measuresCosts, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), TB cases and TB-related deaths.ResultsAmong all evaluated strategies, IGRA with 3HP under DOT was the most cost-effective strategy (US$200.1; 25.1042 QALYs; ICER vs 4R: US$29 182 per QALY gained). The current pre-entry chest X-ray remained the least costly option as screening expenses are borne by applicants. Cost-effectiveness was strongly influenced by screening access and the risk of TB reactivation. At a willingness-to-pay threshold of US$50 000 per QALY gained, IGRA with 3HP under DOT, AI-assisted chest X-ray and IGRA with 4R showed probabilities of cost-effectiveness of 40.0%, 27.4% and 22.9%, respectively. For 122 454 immigrants entering Japan in 2023, IGRA with 3HP under DOT was projected to prevent 1403 TB cases and 479 TB-related deaths.ConclusionsIGRA with 3HP under DOT provides strong cost-effectiveness and preventive impact. IGRA with 1HP under DOT also shows promising potential, contingent on rifapentine pricing and strengthened public health support. Integrating LTBI screening with improved access to screening and healthier living environments may reduce TB reactivation among migrants and promote more equitable health outcomes, particularly for socially vulnerable groups. STRENGTHS AND LIMITATIONS OF THIS STUDY A Markov model was developed to compare multiple latent tuberculosis infection screening and preventive treatment strategies, including both conventional and artificial intelligence-assisted chest X-ray. A Markov model was developed to compare multiple latent tuberculosis infection screening and preventive treatment strategies, including both conventional and artificial intelligence-assisted chest X-ray. One-way, two-way and probabilistic sensitivity analyses were conducted to comprehensively assess parameter uncertainty. One-way, two-way and probabilistic sensitivity analyses were conducted to comprehensively assess parameter uncertainty. The model incorporated TB reactivation rates, treatment completion rates and screening access rates to reflect social vulnerability among migrants. The model incorporated TB reactivation rates, treatment completion rates and screening access rates to reflect social vulnerability among migrants. Epidemiological parameters were derived from published literature and national statistics, ensuring transparency and reproducibility. Epidemiological parameters were derived from published literature and national statistics, ensuring transparency and reproducibility. Multidrug-resistant TB was not included in the model, which may lead to underestimation of disease burden in high-risk subgroups. Multidrug-resistant TB was not included in the model, which may lead to underestimation of disease burden in high-risk subgroups. Introduction Tuberculosis (TB) remains a leading global public health threat, particularly in the context of migration from high-burden to low-incidence settings. Despite ongoing international TB control efforts, substantial gaps persist. The WHO recommends systematic latent TB infection (LTBI) testing and preventive treatment for migrants before arrival in low-incidence countries.1 However, pre-entry chest X-ray screening continues to dominate global protocols, identifying only active TB while leaving LTBI largely unaddressed. As a result, asymptomatic individuals remain at risk of future reactivation, and opportunities for primary prevention are frequently missed, especially among socially vulnerable groups. Migrants from TB-endemic regions often develop active TB soon after resettlement, underscoring the importance of the post-arrival period as a critical window for intervention.2 3 Yet current TB policies rarely account for the timing of reactivation risk or the structural barriers that limit access to screening and treatment, including legal, linguistic and socioeconomic constraints. Japan, a low-incidence country with a TB notification rate of 8.1 per 100 000 population in 2023, has experienced a steady rise in TB cases among foreign-born individuals, now accounting for approximately 16% of all cases.4 In March 2025, Japan introduced mandatory pre-entry chest X-ray screening for migrants from the Philippines, Nepal and Vietnam, and plans are underway to expand the programme to China, Indonesia and Myanmar. Applicants are required to cover the full cost and undergo chest X-ray examinations at designated medical institutions in their countries of origin. Previous cost-effectiveness analyses of LTBI screening have primarily evaluated clinical and economic outcomes for migrants from high-burden countries.57 However, no prior models have incorporated social vulnerability or access barriers that influence screening uptake and treatment completion. To address this gap, we developed a decision-analytic model that explicitly quantifies these factors. The aim of this study is to evaluate the effectiveness and cost-effectiveness of interferon-gamma release assay (IGRA)-based LTBI screening compared with chest X-ray screening for immigrants to Japan. Methods Study design We developed a Markov state-transition model over a lifetime horizon from a public healthcare payer perspective. The base year of the analysis was 2023. The target population comprised asymptomatic BCG-vaccinated 30-year-old immigrants from six high-incidence countries: Philippines, Vietnam, Indonesia, Nepal, Myanmar and China, identified by the Japanese government as high-TB-burden regions. The assumed average age of 30 was derived from the most recent age-group-specific immigration statistics in Japan, which provide detailed age distributions for new immigrants.8 To ensure diagnostic specificity, we excluded the tuberculin skin test (TST) from the model due to its low specificity (59%) in BCG-vaccinated individuals.9 Model outcomes included costs, quality-adjusted life-years (QALYs), incremental cost-effectiveness ratios (ICERs), TB cases and TB-related deaths. A half-cycle correction was applied. We constructed the model using TreeAge Pro 2025 (TreeAge Software, Williamstown, MA). This study follows the Consolidated Health Economic Evaluation Reporting Standards 2022 statement.10 Social vulnerability and access barriers Social vulnerability and access barriers were defined as socioeconomic and structural factors that reduce healthcare utilisation and increase the risk of TB progression among migrant populations for immigrant screening.11 12 To reflect social vulnerability, lower screening access and treatment completion rates and higher reactivation rates were incorporated into the model. Screening strategy We evaluated eleven screening strategies for LTBI in the model, comprising IGRA-based regimens and radiographic approaches. Preventive treatment regimens were selected based on current international guidelines and feasibility in migrant populations. The strategies included: IGRA-based screening with 3-month once-weekly isoniazid (900 mg) plus rifapentine (900 mg) under directly observed therapy (DOT). IGRA-based screening with 3-month once-weekly isoniazid (900 mg) plus rifapentine (900 mg) under directly observed therapy (DOT). IGRA-based screening with 3HP under self-administered therapy (SAT). IGRA-based screening with 3HP under self-administered therapy (SAT). IGRA-based screening with 1-month daily isoniazid (300 mg) plus rifapentine (600 mg) (1HP) under DOT. IGRA-based screening with 1-month daily isoniazid (300 mg) plus rifapentine (600 mg) (1HP) under DOT. IGRA-based screening with 4-month daily self-administered rifampin (600 mg) (4R). IGRA-based screening with 4-month daily self-administered rifampin (600 mg) (4R). IGRA-based screening with 3-month daily self-administered isoniazid (300 mg) plus rifampin (600 mg) (3RH). IGRA-based screening with 3-month daily self-administered isoniazid (300 mg) plus rifampin (600 mg) (3RH). IGRA-based screening with 6-month daily self-administered isoniazid (300 mg) (6H). IGRA-based screening with 6-month daily self-administered isoniazid (300 mg) (6H). IGRA-based screening with 9-month daily self-administered isoniazid (300 mg) (9H). IGRA-based screening with 9-month daily self-administered isoniazid (300 mg) (9H). Current pre-entry chest X-ray conducted at panel clinics in the country of origin. Current pre-entry chest X-ray conducted at panel clinics in the country of origin. Postentry chest X-ray on arrival in Japan. Postentry chest X-ray on arrival in Japan. Postentry artificial intelligence (AI)-assisted chest X-ray using automated interpretation tool. Postentry artificial intelligence (AI)-assisted chest X-ray using automated interpretation tool. No screening. No screening. LTBI screening pathway On arrival, asymptomatic immigrants undergo IGRA testing according to the screening access rate. IGRA-positive individuals with abnormal chest X-ray findings representing old, non-progressive lesions, calcifications or scarring do not receive LTBI treatment under current Japanese clinical pathway. IGRA-negative individuals undergo no further testing or treatment. Individuals with active TB and abnormal chest X-ray findings receive TB treatment. Those with active TB that is not detected by chest X-ray due to its limited sensitivity remain untreated. Chest X-ray-based screening pathway Immigrants receive chest X-ray according to screening access rate. Those with abnormal findings suggestive of active TB receive treatment. Individuals with abnormal findings but no evidence of active disease incur screening costs but do not receive treatment. Those with normal chest X-ray findings receive no treatment. Model parameters Cost Direct medical costs, including IGRA testing, chest X-ray, four LTBI preventive regimens, adverse event management of LTBI treatments and TB treatment, were obtained from Japan’s insurance medical care fee schedule and published literature (online supplemental table 1).13 For rifapentine-containing regimens (1-month daily isoniazid plus rifapentine (1HP) and 3-month once-weekly isoniazid plus rifapentine (3HP)), costs were estimated using the actual import price of rifapentine from the USA. DOT cost was derived from Japan’s long-term care insurance home-visit nursing service fee schedule (2024).14 Indirect costs such as productivity loss and travel expenses were excluded. All costs were converted to US dollars using the 2024 OECD (Organisation for Economic Co-operation and Development) purchasing power parity rate (US$1=¥95.11)15 and discounted at an annual rate of 3%.16 Probability Clinical probabilities were derived from MEDLINE and Japanese TB statistics spanning 1980 to August 2025 (online supplemental table 1). For each parameter, we reviewed several candidate sources from the Japanese and international literature. However, in most cases only one source provided estimates that were directly applicable to our model structure and the target migrant population in Japan; therefore, we selected the single most relevant and methodologically robust source for each parameter. LTBI prevalence and TB incidence were estimated using national surveillance data and published literature.4 17 Sensitivity and specificity values of IGRA, chest X-ray, and AI-assisted chest X-ray; preventive treatment efficacy; completion and adverse event rates; and annual TB reactivation rates by age were sourced from published studies.1826 Annual TB reactivation risk and TB-related mortality among treated and untreated TB cases were obtained from literature,4 27 28 while mortality from other causes was derived from national vital statistics.29 Screening access rate was incorporated into the model to reflect barriers related to legal status, language, environment and financial burden.30 To better represent real-world conditions, both screening access rates and TB reactivation rates were adjusted to account for social vulnerability. Health state utility The model included six health states: no LTBI, LTBI, adverse event from preventive treatment, active TB, cured TB and death (figure 1). Utility values for each health state were obtained from published sources31 32 and discounted at an annual rate of 3%16 (online supplemental table 1). Schematic representation of the Markov cycle tree used in the state transition model. Each ellipse denotes a distinct health state, and arrows indicate the possible transitions between states within a 1-year cycle. LTBI, latent tuberculosis infection; TB, tuberculosis. Data sources Data sources were selected based on relevance to the Japanese context and methodological rigour. Japan-specific data, including costs, TB incidence, LTBI prevalence, screening access rate and completion rates for isoniazid-based regimens, were used whenever available to maximise contextual validity. When Japan-specific data were not available, high-quality international peer reviewed literature was selected based on relevance, methodological rigour and applicability to migrant populations arriving in Japan. To enhance transparency and reproducibility, we documented the country of origin and study year(s) for all parameters. Baseline values, ranges used in one-way sensitivity analyses and distributions for probabilistic sensitivity analyses are summarised in online supplemental table 1. Sensitivity analysis To assess model robustness, we conducted multiple sensitivity analyses. One-way sensitivity analyses were performed to assess the impact of individual parameters on model outcomes. Two-way sensitivity analyses were conducted to evaluate the interaction between screening access rate and TB reactivation multiplier, as well as between completion rates of different LTBI treatment regimens, including 3HP under DOT, 4R and 1HP under DOT. Probabilistic sensitivity analysis was conducted using a second-order Monte Carlo simulation (10 000 iterations). Gamma distributions were applied to cost variables, and beta distributions were used for probabilities, utilities, and test accuracy parameters (online supplemental table 1). A willingness-to-pay (WTP) threshold of US$50 000 per QALY gained was adopted, reflecting Japan’s commonly used benchmark of ¥5 million,33 converted using the 2024 OECD purchasing power parity rate.15 Scenario analysis To inform policy decisions, we conducted scenario analyses comparing the cost-effectiveness and health outcomes of selected LTBI treatment strategies under varying real-world conditions. The analyses focused on two dimensions of social vulnerability and a comparative evaluation of 4R, 1HP DOT and 3HP DOT regimens. The following parameters were varied: Screening access rate: 0.20, 0.50 (base), 0.60, 0.80. Screening access rate: 0.20, 0.50 (base), 0.60, 0.80. TB reactivation multiplier: 0.40, 0.70, 1.00 (base), 2.00. TB reactivation multiplier: 0.40, 0.70, 1.00 (base), 2.00. Completion rate of 1HP DOT: 0.80, 0.85 (base), 1.00. Completion rate of 1HP DOT: 0.80, 0.85 (base), 1.00. Completion rate of 3HP DOT: 0.70, 0.87 (base), 0.90. Completion rate of 3HP DOT: 0.70, 0.87 (base), 0.90. Completion rate of 4R: 0.70, 0.79 (base), 0.90. Completion rate of 4R: 0.70, 0.79 (base), 0.90. Adverse event rate of 4R: 0.010, 0.026 (base), 0.100. Adverse event rate of 4R: 0.010, 0.026 (base), 0.100. Cost of 1HP DOT: US$500.0, US$1000.0, US$2022.0 (base), US$2500.0. Cost of 1HP DOT: US$500.0, US$1000.0, US$2022.0 (base), US$2500.0. All scenarios were evaluated relative to the base condition, which reflects epidemiological and implementation status prior to the turning point. This scenario-based approach enables policymakers to tailor LTBI screening and preventive treatment strategies to the needs of diverse migrant populations, balancing feasibility, equity and cost-effectiveness. Markov cohort analysis We performed the Markov cohort analysis to determine the cumulative lifetime probability of TB cases and TB-related deaths for each strategy. These probabilities were multiplied by the number of 122 454 immigrants who entered Japan from the six target countries in 2023.34 Then, we calculated the number of TB cases and TB-related deaths prevented by the most cost-effective strategy, compared with the current pre-entry chest X-ray. Results Base-case analysis Under the base-case analysis, IGRA with 3HP under DOT was the most cost-effective strategy, with an expected cost of US$200.1 and 25.1042 QALYs, yielding an ICER of US$29 182 per QALY gained versus IGRA with 4R (figure 2, table 1). IGRA with 4R was the next best option (US$148.2; 25.1024 QALYs), with an ICER of US$537 per QALY gained versus the current pre-entry chest X-ray. IGRA with 1HP under DOT produced the second-highest QALYs (25.1040) but at the highest cost among LTBI treatments (US$283.7). For imaging strategies, AI-assisted chest X-ray was more cost-effective than the current pre-entry chest X-ray (US$146.0; 25.0963 QALYs; ICER US$995 per QALY gained). The current pre-entry chest X-ray was the least costly strategy (US$124.0), reflecting applicant-borne screening costs (table 1). Cost-effectiveness plane. The green line indicates the efficiency frontier. The vertical dashed line represents the willingness-to-pay threshold of US$50 000 per QALY gained. 1HP, 1-month daily isoniazid plus rifapentine; 3HP, 3-month once-weekly isoniazid plus rifapentine; 3RH, 3-month daily isoniazid plus rifampin; 4R, 4-month daily self-administered rifampin; 6H, 6-month daily self-administered isoniazid; 9H, 9-month daily self-administered isoniazid; AI, artificial intelligence; DOT, directly observed therapy; IGRA, interferon-gamma release assay; QALY, quality-adjusted life-year; SAT, self-administered therapy. Table 1Base case results: cost-effectiveness and dominance status of screening strategiesStrategyCost (US$)Incremental cost (US$)Effectiveness(QALYs)Incremental effectiveness(QALYs)ICER(US$/QALY gained)Dominance statusNo screening146.9Reference24.9820ReferenceReference–Current pre-entry chest X-ray124.0−22.925.07420.0922−248DominantPostentry chest X-ray142.418.325.07420.0000DominatedDominatedAI-assisted chest X-ray146.03.725.09630.0221166Cost-effective relative to postentry chest X-rayIGRA with 9H156.710.725.09650.000257 374Not cost-effective relative to AI-assisted chest X-rayIGRA with 3RH148.2−8.525.09940.0030−2870DominantIGRA with 3HP under SAT153.75.525.09980.000413 490Extended dominance (higher ICER than IGRA with 3RH)IGRA with 6H147.6−6.125.10090.0011−5623DominantIGRA with 4R148.20.625.10240.0015371Extended dominance (higher ICER than IGRA with 6H)IGRA with 1HP under DOT283.7135.525.10400.001685 748Not cost-effective relative to IGRA with 4RIGRA with 3HP under DOT200.1−83.525.10420.0002−417 349DominantDominant, more effective and less costly than alternative strategies.Extended dominance, more effective and more costly but less efficient than other strategies.AI, artificial intelligence; DOT, directly observed therapy; 6H, 6-month daily self-administered isoniazid; 9H, 9-month daily self-administered isoniazid; 1HP, 1-month daily isoniazid and rifapentine; 3HP, 3-month once-weekly isoniazid plus rifapentine; ICER, incremental cost-effectiveness ratio; IGRA, interferon-gamma release assay; QALY, quality-adjusted life-year; 4R, 4-month daily self-administered rifampin; 3RH, 3-month daily self-administered isoniazid plus rifampin; SAT, self-administered therapy. Base case results: cost-effectiveness and dominance status of screening strategies Dominant, more effective and less costly than alternative strategies. Extended dominance, more effective and more costly but less efficient than other strategies. AI, artificial intelligence; DOT, directly observed therapy; 6H, 6-month daily self-administered isoniazid; 9H, 9-month daily self-administered isoniazid; 1HP, 1-month daily isoniazid and rifapentine; 3HP, 3-month once-weekly isoniazid plus rifapentine; ICER, incremental cost-effectiveness ratio; IGRA, interferon-gamma release assay; QALY, quality-adjusted life-year; 4R, 4-month daily self-administered rifampin; 3RH, 3-month daily self-administered isoniazid plus rifampin; SAT, self-administered therapy. Sensitivity analysis Figure 3 shows a one-way sensitivity analysis (tornado diagram), illustrating how variation in each parameter affects the incremental net monetary benefit. Parameters with longer bars have a greater influence on the results, indicating higher uncertainty impact. One-way sensitivity analysis revealed that the cost-effectiveness comparison between IGRA with 4R and IGRA with 3HP under DOT was most sensitive to the completion rates of 4R and 3HP under DOT, the screening access rate and the TB reactivation multiplier (figure 3). These findings highlight the importance of improving living conditions for immigrant populations and strengthening support for LTBI treatment programmes. Tornado diagram illustrating the incremental net monetary benefit (NMB) of IGRA with 4R versus IGRA with 3HP under DOT. 3HP, 3-month once-weekly isoniazid plus rifapentine; 4R, 4-month daily self-administered rifampin; DOT, directly observed therapy; IGRA, interferon-gamma release assay; LTBI, latent tuberculosis infection; NMB, net monetary benefit; TB, tuberculosis. Two-way sensitivity analysis indicated that IGRA with 3HP under DOT was preferred over IGRA with 4R in regions with higher TB reactivation rates (figure 4A). Conversely, chest X-ray-based screenings are favoured in settings with lower TB reactivation and higher screening access. This figure highlights the substantial impact of regimen completion rates—specifically for 4R, 3HP under DOT and 1HP under DOT—on cost-effectiveness. Two-way sensitivity analyses for key model parameters. (A) TB reactivation and screening access (B) Completion of 4R and 3HP under DOT (C) Completion of 1HP and 3HP under DOT Only cost-effective strategies are shown. 1HP, 1-month daily isoniazid plus rifapentine; 3HP, 3-month once-weekly isoniazid plus rifapentine; 3RH, 3-month daily isoniazid plus rifampin; 4R, 4-month daily self-administered rifampin; 6H, 6-month daily self-administered isoniazid; 9H, 9-month daily self-administered isoniazid; AI, artificial intelligence; DOT, directly observed therapy; IGRA, interferon-gamma release assay; SAT, self-administered therapy; TB, tuberculosis. Higher completion rates of preventive treatment were associated with improved economic outcomes in LTBI treatment strategies between 1HP under DOT, 3HP under DOT and 4R (figure 4B,C). When the completion rate of 4R exceeded 0.81, the completion rate of 3HP DOT fell below 0.85, the screening access rate exceeded 0.67, and the TB reactivation multiplier was below 0.62, IGRA with 4R became more cost-effective than IGRA with 3HP under DOT. At a WTP threshold of US$50 000 per QALY gained, IGRA with 3HP under DOT and IGRA with 4R demonstrated probabilities of cost-effectiveness of 40.0% and 22.9%, respectively (figure 5). The light pink vertical line at US$50 000/QALY marked the policy-relevant threshold, anchoring the analysis within a decision-making framework. Cost-effectiveness acceptability curves and the cost-effectiveness acceptability frontier (CEAF) for alternative screening and treatment strategies across willingness-to-pay thresholds. 3HP, 3-month once-weekly isoniazid plus rifapentine; 4R, 4-month daily self-administered rifampin; DOT, directly observed therapy; IGRA, interferon-gamma release assay; QALY, quality-adjusted life-year. The cost-effectiveness acceptability frontier illustrated the probability of each strategy being the most cost-effective across a range of WTP thresholds, based on probabilistic sensitivity analysis (second-order Monte Carlo simulation, 10 000 iterations) (figure 5). IGRA with 3HP under DOT consistently showed the highest probability of optimality at WTP values above US$30 000 per QALY gained, while IGRA with 4R was preferred at lower thresholds. As WTP increased, IGRA with 3HP under DOT gradually became dominant, reaching a 43.8% probability at US$100 000 per QALY gained (online supplemental table S2). Scenario analysis In scenarios varying the screening access rate—based on an index capturing legal, linguistic, and socioeconomic barriers among immigrants—IGRA with 4R became cost-effective when the access rate exceeded 0.67. AI-assisted chest X-ray also became cost-effective when the screening access rate exceeded 0.71 (online supplemental table S3). In scenarios varying the TB reactivation multiplier—based on an index reflecting living environment and health status—IGRA with 4R became cost-effective when the multiplier fell to 0.62, indicating a reduced annual TB reactivation risk. In scenarios varying the completion rates of 1HP under DOT, 3HP under DOT, and 4R—based on an index measuring healthcare support—IGRA with 1HP under DOT became cost-effective when its completion rate exceeded 0.91 and when the completion rate of 3HP under DOT fell below 0.81. IGRA with 4R became cost-effective when the completion rate of 3HP under DOT fell below 0.85 and when the completion rate of 4R exceeded 0.81. In the scenario considering cost reduction of 1HP under DOT, IGRA with 1HP under DOT became the preferred strategy when its cost fell to US$814.7. Overall, the scenario results suggest that IGRA with 3HP under DOT remains the most cost-effective strategy in the base-case. However, IGRA with 1HP under DOT or 4R may become advantageous under conditions that improve social vulnerability and remove access barriers through targeted support for immigrants. Markov cohort analysis Using a Markov cohort model, we estimated the cumulative lifetime health outcomes—specifically, TB cases and TB-related deaths—associated with two screening strategies: IGRA with 3HP under DOT and the current pre-entry chest X-ray. The analysis was conducted for a cohort of 122 454 immigrants who newly arrived in Japan from six target countries in 2023. Compared with the current pre-entry chest X-ray, IGRA with 3HP under DOT was projected to prevent 1403 TB cases and 479 TB-related deaths over the cohort’s lifetime. Discussion TB screening for immigrant populations not only prevents the transmission of TB from high-burden countries to low-incidence settings but also safeguards the health and well-being of immigrants—both during their stay and on return to their countries of origin. This study demonstrated that, under current conditions, pre-entry chest X-ray remains the most cost-saving strategy. However, IGRA with 3HP under DOT emerged as the most cost-effective approach. IGRA with 1HP under DOT also showed strong potential, particularly in scenarios with higher treatment completion rates or reduced costs for 3HP. Screening access rates and TB reactivation risk were critical determinants of cost-effectiveness. Lower access rates and reduced TB reactivation risks favoured IGRA with 4R. In contrast, higher access rates and elevated reactivation risks led to the superiority of AI-assisted chest X-ray. These findings underscore that the cost-effectiveness of TB screening among immigrant populations is deeply influenced by the socioeconomic environment and the availability of healthcare support for socially vulnerable groups. Addressing access barriers and enhancing support systems may shift the balance towards more effective LTBI screening strategies. This is the first cost-effectiveness analysis to incorporate social vulnerability and access barriers into the evaluation of LTBI screening for immigrants to low-incidence countries. LTBI screening for immigrants has already begun in several low-TB-incidence countries. In the WHO European Region, refugees are routinely screened for active TB in 86.1% of countries and for LTBI in 52.7%.35 In Centers for Disease Control and Prevention guidelines for immigrants and refugee health in the USA, immigrants 2 years of age and older from countries with a WHO-estimated TB incidence rate of ≥20 cases per 100 000 population must undergo an overseas TB screening with an IGRA, with chest X-ray required for all immigrants aged ≥15 years regardless of IGRA results, and for younger individuals with a positive IGRA, TB symptoms, or known HIV infection.36 In 2015/2016, the UK launched a national LTBI testing and treatment programme for new immigrants aged between 16 and 35 years who were born or spent more than 6 months in a high TB incidence country (≥150/100 000 or Sub-Saharan Africa) and entered the UK within the last 5 years.37 In Oman, the Ministry of Health introduced LTBI screening using IGRA as part of the visa medical requirements for residency applications, beginning in August 2024, with free preventive treatment provided when indicated.38 Building on previous evidence, several cost-effectiveness studies have shown the superiority of LTBI screening using IGRA with 3HP by DOT7 39 40 or IGRA with 4R41 supporting the expansion of LTBI screening with preventive treatment in pre-entry programmes. Hontelez and colleagues concluded that LTBI entry screening can be a cost-effective alternative to chest X-ray for immigrants and asylum seekers from high TB endemic countries, provided that completion rates for TB preventive treatment are sufficiently high.42 There are several limitations. First, this model did not consider multidrug-resistant (MDR) TB. Given the very low MDR-TB proportion in Japan (0.6%),4 the impact on the results is expected to be minimal. Second, the model did not include indirect costs (eg, absence from work due to active TB treatment and transportation costs for hospital visits). Excluding indirect costs likely results in conservative estimates, as preventing TB would reduce productivity losses. Third, risk factors for TB, such as diabetes, end-stage renal disease, HIV infection and rheumatoid arthritis, were not taken into account. Omitting these risk factors may underestimate TB risk in high-risk subgroups, leading to conservative estimates of the intervention’s benefits. Finally, the LTBI prevalence and TB incidence in immigrants from six high-incidence countries were derived from the literature rather than real-world data. However, one-way, two-way, probabilistic sensitivity and scenario analyses demonstrated that the core findings remained robust across plausible parameter ranges. Conclusions IGRA-based screening combined with 3HP under DOT offers a cost-effective and life-saving alternative to chest X-ray for newly arrived migrants from high-incidence countries. IGRA with 4R may be the next best option. Moreover, IGRA with 1HP under DOT shows strong potential to become the most cost-effective strategy, contingent on a reassessment of rifapentine pricing and the implementation of robust public health support to ensure high treatment completion. Introducing LTBI screening into immigration TB policies not only reduces the burden of TB disease in the receiving country but also contributes to global TB prevention by reducing the risk of transmission across borders. Supplementary material